Back to results
US 2021/0275667 A1Published application
Antibodies specifically binding to masp-3 for the treatment of various diseases and disorders
AssigneeOmeros Corporation
InventorsW. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
Life of this patent
Estimating the term…
Abstract
The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Claims21
An isolated antibody, or antigen-binding fragment thereof, that binds to MASP-3 comprising:
- a heavy chain variable region comprising a HC-CDR1 set forth as SEQ ID NO:209 XXDIN, wherein X at position 1 is S or T and wherein X at position 2 is N or D;
- a HC-CDR2 set forth as SEQ ID NO:210 WIYPRDXXXKYNXXFXD, wherein X at position 7 is G or D;
- X at position 8 is S, T or R;
- X at position 9 is I or T;
- X at position 13 is E or D;
- X at position 14 is K or E;
- and X at position 16 is T or K;
- and a HC-CDR3 set forth as SEQ ID NO:211 XEDXY, wherein X at position 1 is L or V, and wherein X at position 4 is T or S;
- and a light chain variable region comprising a LC-CDR1 set forth as SEQ ID NO:212 KSSQSLLXXRTRKNYLX, wherein X at position 8 is N, I, Q or A;
- wherein X at position 9 is S or T;
- and wherein X at position 17 is A or S;
- a LC-CDR2 set forth as SEQ ID NO:144 WASTRES and a LC-CDR3 set forth as SEQ ID NO:146 KQSYNLYT.
9 more elements
Dependencies are inferred from the claim text.